

287510

innovene



June 20, 2005

U.S. Environmental Protection Agency
Office of Pollution Prevention and Toxics
EPA East Building, Room 6428
1201 Constitution Avenue, NW
Washington, DC 20004

CONTAIN NO CBI

8EHQ-0705-16093

2005 JUL -6 AM 11:17

RECEIVED
OPPT/CBI

Attention: TSCA 8(e) Coordinator

Re: Acute Inhalation Toxicity Study of Acrylonitrile in Rats


Dear Sir or Madame:

On behalf of study co-sponsors Innovene USA, LLC and SNF S.A.S., I am submitting this letter pursuant to Section 8(e) of the Toxic Substances Control Act (TSCA) to inform the Environmental Protection Agency (EPA) of data obtained from an acute inhalation toxicity study conducted on Acrylonitrile (CAS number 107-13-1).

The objective of this study was to determine the acute inhalation toxicity of Acrylonitrile when administered as a vapor for a single, 4-hour, nose-only exposure to rats. The test protocol was designed to be in general compliance with OECD Test Guideline 403 and the European Union Guideline in the Official Journal of the European Union (L 383A, Volume 35, B2). The test article was administered to 5 groups of five male and five female Crl:CD® (SD) albino rats via nose-only exposure as a vapor at concentrations of 539, 775, 871, 1006 or 1181 ppm. Based on the results of this study, the 4-hour LC₅₀ of acrylonitrile vapor by nose-only exposure was 946 ppm.

Relevant treatment-related findings immediately following exposure included tremors for all groups; ataxia in the 775, 851, 1106 and 1181 ppm groups; and hypoactivity in the 775, 871 and 1006 ppm groups. Relevant findings for the surviving animals during the 14-day post-exposure observation period included ataxia in the 775 and 871 ppm groups; and tremors and hypoactivity in the 871 and 1006 ppm groups. All surviving animals were considered normal by the end of the study.

Some of these effects of acrylonitrile vapor have been previously reported to the Agency by others, and at lower exposure levels. They were observed, however, in studies conducted with whole-body exposure instead of nose-only exposure. Innovene has made no determination as to whether the information included herein corroborates other reports or whether it presents new information of "a substantial risk of injury to health or environment," as defined by relevant guidance. We have decided that it would be prudent to submit this information at this time. We will provide a full copy of the final report when it becomes available.



If you have any questions, please contact me at 630-420-5124 or
kevin.diesen@innovene.com.

Sincerely,

Handwritten signature of Kevin W. Diesen in cursive script.

Kevin W. Diesen
Manager, Innovene Product Stewardship & Toxicology